Latest Articlesddd
When plenty of news comes out of the biotech sector, we are left with no option …
EXELIXIS APPROVED PRODUCTS 1. CABOMETYX™(CABOZANTINIB) For Exelixis (EXEL) the two approved oncology products cabozantinib and cobimetinib …
Following recent reports of new onset or worsening peripheral neuropathy in patients with ATTR amyloidosis with …
News about investigational drugs, which are expected to make big differences in the lives of people …
EXELIXIS (EXEL) Friends and subscribers are asking the following question for more than two weeks now: …
The FDA approval of Sarepta’s (SRPT) Duchenne muscular dystrophy (DMD) product, Exondys 51 (eteplirsen), surprised many …
As we expected in our previous articles, Today, Aerie Pharmaceuticals (AERI) came up with great news …
Another gene editing firm, CRISPR Therapeutics decided to become publicly traded. On Friday, the private firm …
The FDA announced what made Clovis Oncology (CLVS) shareholders believe that the bad times might have …
Xoma’s (XOMA) webcast and conference call scheduled for September 15, 2016, at 1:30 p.m. PDT (4:30 …
Filled with high hopes and great enthusiasm, we are following up on Nektar’s (NKTR) immunotherapy product …
At the European Society of Cardiology Congress 2016 in Rome, Italy, Array Biopharma (ARRY) presented good …
Benign Prostate Hypertrophy (BPH) Is Fexapotide the Safest and Effective Prostate Cancer Preventative? That’s what Nymox …
Pfizer accepted to pay $14 billion in cash to acquire Medivation. It is important for investors …
AMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis The Company is Radius …
Advaxis (ADXS) is a small clinical-stage biotech producing and developing cancer immunotherapy products based on its …
JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis The Company is …
What’s Going on the Morning of Thursday, August 18, 2016? PORTOLA Portola Pharmaceuticals (PTLA) announced the …
GILEAD & GENMAB To Access Genmab’s (GEN) bispecific antibody technology, Gilead (GILD) signed a new agreement …
Gene Editing EDITAS MEDICINE CRISPR gene editing firm Editas Medicine (EDIT) signed a collaboration agreement with …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
